A Multicenter, Open-label, Safety Extension Study With Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008213/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to continue to characterize the safety profile of benralizumab
administration and monitor the pharmacodynamic activity of the drug in those asthma patients
who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor
study D3250C00021 (BORA, NCT02258542).
提供机构：
Vivli
创建时间：
2022-07-06
